Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Destiny Pharma Limited - In Liquidation logo — Mark Smith and Stephen Cork were appointed Administrators on...

Destiny Pharma Limited - In Liquidation

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability.

Founded 1997 United Kingdom Brighton, United Kingdom 10 employees Post Ipo Equity Biotechnology, Health Care +1

General Information

Company Name Destiny Pharma Limited - In Liquidation
Founded Year 1997
Location United Kingdom Brighton, United Kingdom +1
Employees 10
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Destiny Pharma Limited - In Liquidation moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Destiny Pharma Limited - In Liquidation

Destiny Pharma Limited, a United Kingdom-based biotechnology firm founded in 1997, is now In Liquidation under the administration of Mark Smith and Stephen Cork as of 21 August 2024. Despite its innovative pipeline, the company has entered a critical phase of administration owing to its operational circumstances.

The company specializes in the development of groundbreaking medicines aimed at preventing life-threatening infections. Key assets include NTCD-M3, a promising Phase 3 treatment intended to prevent recurrences of C. difficile infection, and XF-73 nasal gel, which concluded a successful Phase 2b trial. Their joint venture aims to develop SPOR-COVTM, targeting COVID-19 prevention.

The last financial boost saw a Post-IPO Equity investment on 16 March 2023. This status indicates potential risks and opportunities for future stakeholders, given its extensive R&D and innovative edge in biotherapeutics.

Taxonomy: Clinical Stage Biotechnology, Novel Medicines Development, Microbiome-based Biotherapeutics, C. difficile Infection Prevention, Hospital Acquired Infection Control, Phase 3 Clinical Trials, Post-Surgical Infection Prevention, Staphylococcal Infection Prevention, MRSA Prevention, COVID-19 Prevention, Viral Respiratory Infection Prevention, Antimicrobial Resistance Solutions, Drug-resistant Bacteria Control, SPOR-COVTM Development, XF Drug Series Research

Services & Products

development of anti-infectives
prevention of bacterial infections
clinical trials

Target Customers

hospitals healthcare providers medical professionals biotechnology investors

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 16 Mar 2023
Grant •••••• - 12 Jul 2022
Grant •••••• - 29 Jan 2019
Post-IPO Equity •••••• - 04 Dec 2017
Venture - Series Unknown •••••• - 04 Sep 2017

View All 7 Funding Rounds

Destiny Pharma Limited - In Liquidation Alternatives & Competitors

View All Alternatives
Destiny Pharma Limited - In Liquidation vs
Microbion Corporation
Microbion Corporation United States

Developing a disruptive new class of therapeutic drugs for the treatment of rare, chronic, and serio...

Series Unknown
16 employees
Biotechnology, Health Care
Destiny Pharma Limited - In Liquidation vs
Dr Temp Medical & Hospital Supplies
Dr Temp Medical & Hospital Supplies South Africa

Clinical Quality, Innovative Simplicity

23 employees
Destiny Pharma Limited - In Liquidation vs
Replicor Inc.
Replicor Inc. Canada

292 million people have chronic hepatitis B. We're developing the cure.

6 employees
Biotechnology, Health Care
View all alternatives

FAQ About Destiny Pharma Limited - In Liquidation

Mark Smith and Stephen Cork were appointed Administrators on 21 August 2024, and act without personal liability.
Destiny Pharma Limited - In Liquidation was founded in 1997.
Destiny Pharma Limited - In Liquidation is headquartered in Brighton, United Kingdom.
Destiny Pharma Limited - In Liquidation operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Destiny Pharma Limited - In Liquidation has approximately 10 employees.
Destiny Pharma Limited - In Liquidation has completed 7 funding rounds. The latest funding stage is Post Ipo Equity.
Destiny Pharma Limited - In Liquidation offers: development of anti-infectives, prevention of bacterial infections, clinical trials.
Top alternatives and competitors to Destiny Pharma Limited - In Liquidation include Microbion Corporation, Dr Temp Medical & Hospital Supplies, Replicor Inc., Inivos, Peptilogics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Destiny Pharma Limited - In Liquidation and Microbion Corporation are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Destiny Pharma Limited - In Liquidation and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy